• Explore /
  • Poster
  • / Are we systemically under treating cisplatin-eligible patients with muscle invasive bladder cancer (MIBC) who are undergoing bladder preservation by chemoradiotherapy?

Are we systemically under treating cisplatin-eligible patients with muscle invasive bladder cancer (MIBC) who are undergoing bladder preservation by chemoradiotherapy?

Abstract Poster

Authors

null

Srikala S. Sridhar

Princess Margaret Cancer Centre, Toronto, ON, Canada

Srikala S. Sridhar , Shaheena Bashir , Peter W. M. Chung , Alexandre Zlotta , Neil Eric Fleshner , Robert G. Bristow , Girish S. Kulkarni , Miriam Teich , Nimira S. Alimohamed , Gregory Lo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, and Testicular Cancers

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Urothelial Carcinoma

Citation

J Clin Oncol 34, 2016 (suppl 2S; abstr 417)

DOI

10.1200/jco.2016.34.2_suppl.417

Abstract #

417

Poster Bd #

H10

Abstract Disclosures

Similar Posters

First Author: Qian Shi

First Author: John J Coen

First Author: Toshiki Kijima

First Author: Vadim S. Koshkin